Bristol Myers Squibb Growth Drugs Surge 17% in 9M 2025, Offsetting 16% Decline in Legacy Portfolio Sales
Summary
Bristol Myers Squibb (BMY) reported a robust 17% increase in sales from its growth drug portfolio during the first nine months of 2025. This strong performance was critical in mitigating a significant 16% decline in revenue generated by the company's older, legacy products. The data underscores the pharmaceutical giant's ongoing portfolio transition, where newer assets must rapidly scale up to compensate for revenue erosion from drugs facing patent expiration and generic competition, setting the stage for top-line expansion challenges into 2026.
Bristol Myers Squibb saw growth drug sales rise 17% in the first nine months of 2025. This strong performance was critical in offsetting a 16% decline in older, legacy product revenue. The firm's ability to sustain this growth is key to 2026 top-line expansion.
Key Takeaways
- Growth drug sales increased by a robust 17% in the first nine months of 2025.
- Legacy product revenue simultaneously experienced a significant 16% sales decline.
- Sustained performance of newer assets is vital for achieving 2026 revenue expansion.
Sentiment: Neutral
Strong growth in new drugs is currently balanced by substantial revenue erosion in legacy products.
Disclaimer: This is an AI-generated summary of a press release . The model used to summarize this release may make mistakes. See the full release here.
